A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 14 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Oct 2009 New trial record